Pfizer expects to have delivered 200 million doses to the US by the end of May, hitting the mark two months ahead of its contractual obligation.
The company said it can potentially make a total of 2 billion doses worldwide by the end of 2021, based on expansion at its current facilities and “contingent upon adding more suppliers and contract manufacturers,” though it’s unsure if it will actually sell all those doses.
Pfizer is coming out of a major corporate restructuring, spinning off several parts of its business to focus on developing and distributing more innovative medicines. Although it’s playing a major role in fighting coronavirus,
Pfizer’s broader business was challenged by the pandemic — fewer people leaving home to see their doctors meant fewer new prescriptions for some of Pfizer’s key products during much of 2020. But it expects a “continued recovery” in broader healthcare activity in 2021 as more people become vaccinated.